#OpenAI
Total 344 articles
A $10B funding collapse for Oracle's OpenAI data center signals a market reality check. PRISM analyzes the impact on AI infrastructure and investment.
OpenAI's new image editing AI commoditizes photorealistic manipulation, challenging the future of media, trust, and the very concept of photographic proof.
OpenAI's ChatGPT app store is more than a feature. It's a strategic move to build the next OS, igniting a new platform war and a developer gold rush.
PRISM by Liabooks
Place your ad in this space
[email protected]Google's Gemini 3 Flash is more than a faster AI model. It's a strategic move to commoditize AI, shifting the battle from performance to scale. Here's why it matters.
OpenAI's quiet reversal of a key ChatGPT feature reveals a critical truth: speed is beating raw intelligence in the AI race. Our analysis on why this is a major win for Google.
OpenAI's AI for biology is more than a paper. It's a strategic play to upend the multi-trillion dollar pharma industry. Here's our expert analysis.
OpenAI's FrontierScience benchmark signals a strategic pivot from chatbots to automating scientific discovery. A deep dive into why this changes the game for R&D and tech investors.
PRISM by Liabooks
Place your ad in this space
[email protected]OpenAI's new GPT-Image-1.5 model is more than a speed upgrade. It's a strategic move to dominate the enterprise AI space. Our analysis explains why.
OpenAI's quiet GPT-5.2 update is a strategic signal. Our analysis reveals why this shift from hype to stability marks a new, more mature era for the AI industry.
OpenAI's comms chief Hannah Wong is leaving. Her exit signals a major strategic shift from crisis management to corporate maturity. Here's what it means for the AI industry.
Disney's OpenAI deal isn't a simple partnership. Discover the strategic genius behind its one-year exclusivity clause and how it sets the stage for a massive AI bidding war.
PRISM by Liabooks
Place your ad in this space
[email protected]Chai Discovery's $130M raise at a $1.3B valuation isn't a funding story. It's a signal that elite AI talent is targeting pharma's core business model.